Epinastine hydrochloride is a Small Molecule owned by Boehringer Ingelheim International, and is involved in 25 clinical trials, which were completed.

Epinastine Hydrochloride is an histamine H1 receptor antagonist without sedative activity. Epinastine hydrochloride blocks the histamine H1 receptor and inhibits the release of histamine from mast cells. This prevents the typical allergic symptoms that are caused by histamine activity on capillaries, skin, mucous membranes, and on gastrointestinal and bronchial smooth muscles. Typical histamine activities include vasodilation, bronchoconstriction, increased vascular permeability, pain, itching, and spasmodic contractions of gastrointestinal smooth muscles. Epinastine also has affinity for the histamine H2, 5-HT2, and the alpha-1, alpha-2 adrenergic receptors.

The revenue for Epinastine hydrochloride is expected to reach a total of $3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Epinastine hydrochloride NPV Report.

Epinastine hydrochloride is currently owned by Boehringer Ingelheim International. Santen Pharmaceutical is the other company associated in development or marketing of Epinastine hydrochloride.

Epinastine hydrochloride Overview

Epinastine hydrochloride is under development for allergic conjunctivitis. It is non-sedative, highly effective anti-allergic agent. It is formulated as tablets, solution and syrup for oral route drops solution for ophthalmic route of administration. It is mainly indicated to treat bronchial asthma, allergic rhinitis, psoriasis vulgaris associated with hives, eczema, dermatitis, pruritus, prurigo, pruritus cutaneous layer.

It was also under development for allergic rhinitis in United States and Canada by Inspire Pharmaceuticals.

Santen Pharmaceutical Overview

Santen Pharmaceutical (Santen) focuses on the research, development, manufacturing and marketing of pharmaceutical products and medical devices. Its product portfolio includes prescription ophthalmic products for glaucoma, bacterial conjunctivitis, dry eye, inflammation, cataract, muscae volitantes, diabetic retinopathy, retinal detachment, hyposphagma, myopia, retinal detachment, amblyopia, astigmatism, strabismus, hordeolum, VDT syndrome and others; over-the-counter products ophthalmic products; anti-allergy ophthalmic products; and medical devices such as intraocular lenses (IOLs) and other ophthalmic products. Santen operates through its group companies located in Asia, Europe and the US. It operates production facilities in Noto, and Shiga, Japan; and Suzhou, China. Santen is headquartered in Kita-ku, Osaka, Japan.

The company reported revenues of (Yen) JPY266,257 million for the fiscal year ended March 2022 (FY2022), an increase of 6.7% over FY2021. In FY2022, the company’s operating margin was 14%, compared to an operating margin of 4.9% in FY2021. In FY2022, the company recorded a net margin of 10.2%, compared to a net margin of 3.7% in FY2021. The company reported revenues of JPY63,382 million for the second quarter ended September 2022, a decrease of 3.3% over the previous quarter.

Quick View – Epinastine hydrochloride

Report Segments
  • Innovator (NME)
Drug Name
  • Epinastine hydrochloride
Administration Pathway
  • Nasal
  • Ophthalmic
  • Oral
Therapeutic Areas
  • Dermatology
  • Immunology
  • Ophthalmology
  • Respiratory
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.